Literature DB >> 9677444

Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression.

F Guddo1, A Giatromanolaki, C Patriarca, J Hilkens, C Reina, R M Alfano, A M Vignola, M I Koukourakis, M Gambacorta, G Pruneri, G Coggi, G Bonsignore.   

Abstract

Carcinoma cell detachment is an important step in tumor progression and metastasis. Episialin (EMA), if expressed throughout the entire cell surface, may inhibit cell-cell and cell-matrix adhesion. We investigated whether the cellular distribution of episialin in non-small cell lung cancer (NSCLC) is associated with tumor progression. We evaluated the expression of episialin by immunohistochemical staining, in surgical specimens from 122 adenocarcinomas and 99 squamous cell carcinomas. Episialin was present in most NSCLC, with a higher percentage of immunoreactive neoplastic cells in adenocarcinoma than in squamous cell carcinoma (p = 0.0001). In adenocarcinoma the depolarized pattern was significantly associated with nodal metastasis (p = 0.005) and with advanced stage (p = 0.007). In conclusion, nodal metastasis and advanced pathological stage in adenocarcinoma are associated with a depolarized cellular distribution of episialin, suggesting a possible involvement of the molecule in cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9677444

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways.

Authors:  Mengying Yao; Weihong Zhang; Qingxian Zhang; Lihua Xing; Aiguo Xu; Qiuhong Liu; Bing Cui
Journal:  Lung       Date:  2011-10-01       Impact factor: 2.584

2.  Mucin-1 correlates with survival, smoking status, and growth patterns in lung adenocarcinoma.

Authors:  Elisa Lappi-Blanco; Johanna M Mäkinen; Siri Lehtonen; Henna Karvonen; Raija Sormunen; Kirsi Laitakari; Shirley Johnson; Riitta Mäkitaro; Risto Bloigu; Riitta Kaarteenaho
Journal:  Tumour Biol       Date:  2016-08-01

3.  MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

Authors:  R L ten Berge; F G Snijdewint; S von Mensdorff-Pouilly; R J Poort-Keesom; J J Oudejans; J W Meijer; R Willemze; J Hilgers; C J Meijer
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

4.  Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer.

Authors:  Dongrong Situ; Jian Wang; Yun Ma; Zhihua Zhu; Yi Hu; Hao Long; Tiehua Rong
Journal:  Med Oncol       Date:  2010-11-30       Impact factor: 3.064

5.  MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion.

Authors:  Jingchun Gao; Matthew J McConnell; Bin Yu; Jiannong Li; Justin M Balko; Esther P Black; Joseph O Johnson; Mark C Lloyd; Soner Altiok; Eric B Haura
Journal:  Int J Oncol       Date:  2009-08       Impact factor: 5.650

6.  Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.

Authors:  Pawel Ciborowski; Olivera J Finn
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 7.  Glycosylation Changes in Brain Cancer.

Authors:  Lucas Veillon; Christina Fakih; Hadi Abou-El-Hassan; Firas Kobeissy; Yehia Mechref
Journal:  ACS Chem Neurosci       Date:  2017-11-07       Impact factor: 4.418

8.  MUC1 drives c-Met-dependent migration and scattering.

Authors:  Teresa M Horm; Benjamin G Bitler; Derrick M Broka; Jeanne M Louderbough; Joyce A Schroeder
Journal:  Mol Cancer Res       Date:  2012-11-27       Impact factor: 5.852

9.  Clinical associations of mucin 1 in human lung cancer and precancerous lesions.

Authors:  Andreas Saltos; Farah Khalil; Michelle Smith; Jiannong Li; Michael Schell; Scott J Antonia; Jhanelle E Gray
Journal:  Oncotarget       Date:  2018-11-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.